Evaluation and application of population pharmacokinetic models for optimising linezolid treatment in non-adherence multidrug-resistant tuberculosis patients
European Journal of Pharmaceutical Sciences · 2024
DOI: 10.1016/j.ejps.2024.106915 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pharmaceutical Sciences, 2024. Verfasst von Rong Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Centre for Infec…. Hauptthemen laut MEDLINE: Linezolid, Tuberculosis, Multidrug-Resistant, Antitubercular Agents, Models, Biological. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
BACKGROUND: Population pharmacokinetic (popPK) models can optimise linezolid dosage regimens in patients with multidrug-resistant tuberculosis (MDR-TB); however, unknown cross-centre precision and poor adherence remain problematic. This study aimed to assess the predictive ability of published models and use the most suitable model to optimise dosage regimens and manage compliance. METHODS: One hundred fifty-eight linezolid plasma concentrations from 27 patients with MDR-TB were used to assess the predictive performance of published models. Prediction-based metrics and simulation-based visual predictive checks were conducted to evaluate predictive ability. Individualised remedial dosing regimens for various delayed scenarios were optimised using the most suitable model and Monte Carlo simulations. The influence of covariates, scheduled dosing intervals, and patient compliance were assessed. RESULTS: Seven popPK models were identified. Body weight and creatinine clearance were the most frequently identified covariates influencing linezolid clearance. The model with the best performance had a median prediction error (PE%) of -1.62 %, median absolute PE of 29.50 %, and percentages of PE within 20 % (F20, 36.97 %) and 30 % (F30, 51.26 %). Monte Carlo simulations indicated that a twice-daily 300 mg linezolid dose may be more efficient than 600 mg once daily. For the 'typical' patient treated with 300 mg twice daily, half the dosage should be taken after a delay of ≥ 3 h. CONCLUSIONS: Monte Carlo simulations based on popPK models can propose remedial regimens for delayed doses of linezolid in patients with MDR-TB. Model-based compliance management patterns are useful for balancing efficacy, adverse reactions, and resistance suppression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Centre for Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China.
- Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Centre for Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China; D…
- Department of Infectious Diseases, Hunan University of Medicine General Hospital, Huaihua, Hunan, 418000, China.
- Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Centre for Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China. E…
- Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, 200040, China. Electronic address: jmao12@fudan.edu.cn.
- Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Centre for Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China; N…
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Li, R., Sun, F., Feng, Z., Zhang, Y., Lan, Y., Yu, H., Li, Y., Mao, J., & Zhang, W. (2024). Evaluation and application of population pharmacokinetic models for optimising linezolid treatment in non-adherence multidrug-resistant tuberculosis patients. European Journal of Pharmaceutical Sciences. https://doi.org/10.1016/j.ejps.2024.106915
Vancouver
Li R, Sun F, Feng Z, Zhang Y, Lan Y, Yu H, et al. Evaluation and application of population pharmacokinetic models for optimising linezolid treatment in non-adherence multidrug-resistant tuberculosis patients. European Journal of Pharmaceutical Sciences. 2024. doi:10.1016/j.ejps.2024.106915
BibTeX
@article{Li2024,
author = {Li, Rong and Sun, Feng and Feng, Zhen and Zhang, Yilin and Lan, Yuanbo and Yu, Hongying and Li, Yang and Mao, Junjun and Zhang, Wenhong},
title = {Evaluation and application of population pharmacokinetic models for optimising linezolid treatment in non-adherence multidrug-resistant tuberculosis patients},
journal = {European Journal of Pharmaceutical Sciences},
year = {2024},
doi = {10.1016/j.ejps.2024.106915}
}
EUVIMED